← Ticker index
HIMS
Ticker
HIMS
Congressional Trades
5
by 2 members
Ticker disclosure brief
Congressional disclosure records for HIMS
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Tony Wied
BUY · 2026-02-03
Largest range
$500K – $1.0M
Tony Wied
Longest observed gap
42d
Lisa McClain
Highest 30d vs SPY
26.0%
Tony Wied
Purchase rows
5
100%
Sale rows
0
0%
Disclosed midpoint
$1.5M
range estimate
Unique Traders
2
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats0 · 0%
Republicans5 · 100%
Lobbying filings
all →- 2026-07-08$60KHIMS & HERS HEALTH INC.Issues related to telehealth. Issues related to access to compounded drugs and drug shortages. Issues related to Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances. Issues related to diagnostic services.
- 2026-04-20$360KHIMS & HERS HEALTH INC.Matters related to compounding, telehealth, and healthcare
- 2026-04-17$60KHIMS & HERS HEALTH INC.Compounding / telehealth / healthcare
- 2026-04-09$60KHIMS & HERS HEALTH INC.Issues related to telehealth. Issues related to access to compounded drugs and drug shortages. Issues related to Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances.
- 2026-01-23$330KHIMS & HERS HEALTH INC.Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances Discussions concerning proposed legislation related to access to compounded drugs and drug shortages H.R.5316 - Drug Shortage Compounding Patient Access Act of 2025 H.R.4605 - End Prescription Drug Ads Now Act H.R.238 - Healthy Technology Act of 2025 S.5040 - Protecting Patients from Deceptive Drug Ads Online Act S.2068 - End Prescription Drug Ads Now Act
- 2026-01-23$320KHIMS & HERS HEALTH INC.Telehealth Compounded medicines Quality and safety manufacturing
- 2026-01-23$240KHIMS & HERS HEALTH INC.Drug shortage list FDA transparency
- 2026-01-20$60KHIMS & HERS HEALTH INC. (FORMERLY HIMS INC)Compounding / telehealth / healthcare Compounding / telehealth / healthcare
- 2026-01-16$280KHIMS & HERS HEALTH INC.Matters related to compounding, telehealth, and healthcare
- 2026-01-15$60KHIMS & HERS HEALTH INC.Issues related to telehealth. Issues related to access to compounded drugs and drug shortages. Issues related to Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances.
Loading trade analytics…
All Disclosed Trades
Page 1 · 5 of 5 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-02-03 | RTony Wied | BUY | $500K – $1.0M | 34d | receipt → |
| 2026-02-03 | RTony Wied | BUY | $500K – $1.0M | 34d | receipt → |
| 2025-08-04 | RLisa McClain | BUY | $1K – $15K | 42d | receipt → |
| 2025-08-04 | RLisa McClain | BUY | $1K – $15K | 39d | receipt → |
| 2025-08-04 | RLisa McClain | BUY | $1K – $15K | 39d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.